SARS-CoV-2 Virologic Rebound With Nirmatrelvir–Ritonavir Therapy - An Observational Study, Annals of Internal Medicine, 14 November 2023.

[cujoe]

This is a follow-up to CLLerinOZ's post 2 months back on Paxlovid guidelines - this time from research out of the US. It profiles a 1 in 5 incidence in "Virological Rebound" in adults receiving nirmatrelvir–ritonavir (Paxlovid) therapy. Fortunately, while associated with shedding of replication-competent virus, it seems not to be causing post-VR resistance mutations.

Full access link to the paper:

SARS-CoV-2 Virologic Rebound With Nirmatrelvir–Ritonavir Therapy - An Observational Study, Annals of Internal Medicine, Original Research, 14 November 2023.

acpjournals.org/doi/10.7326...

And link to CLLerinOZ's earlier post:

Current use of Paxlovid guidelines and issues in Sept 2023

healthunlocked.com/cllsuppo...

Stay Safe & Well,

Ciao - Cujoe

[MateoBeach]

Guess It ain’t over until your own immune system says it’s over. S&W.

[Justasheet1]

cujoe,

Interesting for me was in 11/2022, I had a rebound and in 11/2023 I didn’t.

Jeff